SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of advanced diagnostic products, announced today that it has agreed to provide $300,000 of funding over a two-year period to support the nanotechnology research of Michael Heller, Ph.D., professor in the Department of Bioengineering at Jacobs School of Engineering, University of California, San Diego (UCSD) and cofounder of Nanogen. Dr. Heller's research under this grant will focus on exploring further use of electric field-based technology for nanofabrication and assembly of nanostructures as well as the integration of nanostructures with other devices. The funding will be used to advance nanotechnology and nanofabrication applications that are related to the intellectual property position held by Nanogen and UCSD while the company focuses its internal efforts on commercial products for medical diagnostics. "This agreement allows us to support the pioneering work of Dr. Heller and the University," said Howard Birndorf, chairman and chief executive officer of Nanogen, Inc., who further stated his belief that, "Nanotechnology applications will be the key to future advances in medical research. We believe that development of nanotechnology will enable highly sophisticated, cost efficient point-of-care diagnostics." "I am very pleased that Nanogen has agreed to provide this two-year funding to support the nanotechnology research of Dr. Michael Heller," said Shu Chien, M.D., Ph.D., chair of UCSD's Department of Bioengineering, professor of Bioengineering and Medicine, and director of the Whitaker Institute of Biomedical Engineering. "The Department of Bioengineering is interested in fostering innovative research that can be translated to industrial or clinical applications. Dr. Heller is doing cutting-edge research that will advance our knowledge in the frontier areas of nanotechnology and nanofabrication, and I look forward to seeing the fruits of this academia-industry partnership, which will generate significant knowledge in science and valuable benefits to people." Dr. Heller's ongoing research is based on Nanogen's electric field-based technology to demonstrate the application of this unique platform in nanofabrication of precision nanoparticles. Nanogen's patent portfolio currently includes over forty U.S. patents and patent applications based on intellectual property developed by Dr. Heller; over ten of those relate to work on nanofabrication he conducted while he was employed by the company. Nanogen will have a priority position to obtain any intellectual property rights developed under this current research agreement with UCSD. About Nanogen, Inc. Nanogen's advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarrays and analyte specific reagents to develop tests to detect mutations associated with genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen's subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen's ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen's website at www.nanogen.com. Forward-Looking Statement This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.